Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-reveals-effectiveness-of-tea-for-treating-liver-cancer-with-a-70-chance-of-completely-destroying-tumor
https://www.med.cuhk.edu.hk/press-releases/cuhk-reveals-effectiveness-of-tea-for-treating-liver-cancer-with-a-70-chance-of-completely-destroying-tumor

CUHK Reveals Effectiveness of TEA for Treating Liver Cancer with a 70% Chance of Completely Destroying Tumor

The Faculty of Medicine at The Chinese University of Hong Kong (CUHK) has recently achieved a breakthrough in research on the treatment of primary liver cancer (hepatocellular carcinoma, HCC). Comparing with the conventional Transarterial chemoembolization (TACE), the research team proved that the new Transarterial Ethanol Ablation (TEA) is more effective in killing cancer cells with a 70% chance of completely destroying the tumor. This pioneering research was presented with the Best Paper Award in the Congress of Interventional Oncology in 2013 and published in an international leading medical journal, Radiology, in 2014. 

 

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer deaths worldwide, particularly common in Asian countries. More than 700,000 people are newly diagnosed with the disease globally every year. According to the Department of Health, HKSAR Government, there were on average 1,798 new cases of HCC and 1,501 deaths due to HCC annually in Hong Kong between 2008 and 2013. 

 

Patients with early stage of HCC are treated with liver resection or local ablation, which are applicable to about 30% of all patients. For patients with intermediate stage of the cancer, liver resection or local ablation is no longer an option, they account for another 30% of all patients and are treated with transarterial therapy. For patients with advanced disease, molecular targeted therapy or supportive care will be given. 

 

Transarterial therapy is the most common treatment for primary liver cancer, it is proved effective in prolonging patient survival, and can be given repeatedly if necessary, therefore it plays an important role in the treatment algorithm of liver cancer. Conventional transarterial chemoembolization (TACE), a method that was introduced thirty years ago, is currently the most common form of transarterial treatment for primary liver cancer in Hong Kong and all over the world. Although other forms of transarterial treatment have been introduced in the recent five to ten years, such as drug-eluting beads and selective internal radiation (radioembolization), these treatments have not gained popularity because they have not been shown to be more effective than conventional TACE in recent researches, and they are much more expensive. 

 

Prof. Simon Yu, Professor of the Department of Imaging and Interventional Radiology at CUHK and Director of Vascular & Interventional Radiology Foundation Clinical Science Centre, CUHK, has started his research on the use of TEA for treating HCC since 2001. Through animal experiments, pharmacokinetics and clinical studies, the treatment was found to be safe and effective. According to his research, treatment related mortality was 0%. The median overall survival rate of patients after treatment was 26 months, much longer than the 6 months median overall survival in patients without treatment. To compare the safety and effectiveness of TEA versus TACE for treating HCC, the research team led by Prof. Yu conducted a randomized controlled trial from 2007 to 2012. Patients with intermediate stage HCC, aged 26 to 88, were randomly assigned into two groups. Each group consisted of 48 patients who received TEA and TACE respectively. The findings showed 0% treatment related mortality in both groups and indicated no difference in treatment safety between TEA and TACE. Most importantly, TEA was found to be more effective in completely eradicating tumor cells within the tumor, compared with TACE. 

 

 TEATACE
Complete absence of tumor in 3 months70.5%51.3%
Median progression free survival14.8 months9.3 months
Median overall survival24.3 months20.1 months

 

Professor Yu pointed out that the finding is a breakthrough for transarterial treatment of HCC. 'Our research team will continue to conduct research in order to further improve the effectiveness of TEA.'

 

The research team is now recruiting patients with HCC for the second round of research. Inclusion criteria include tumors of intermediate tumor stage, not more than 5 tumors, not more than 12cm and not received any treatment before. Interested patients are invited to contact the research team at 35053211 or 35052046.

 

 

Prof. Simon Yu, Professor, Department of Imaging and Interventional Radiology at CUHK

Prof. Simon Yu, Professor, Department of Imaging and Interventional Radiology at CUHK, introduces the effectiveness of Transarterial Ethanol Ablation (TEA) treatment on liver cancer.

More Press Releases

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
CUHK Research Team Develops an AI System for Detecting COVID-19 Infections in CT with a Privacy Preserving Multinational Validation Study

CUHK Research Team Develops an AI System for Detecting COVID-19 Infections in CT with a Privacy Preserving Multinational Validation Study

Research
CUHK Identifies Outcome Indicators for Benign Prostatic Hyperplasia Patients Receiving Prostatic Artery Embolisation

CUHK Identifies Outcome Indicators for Benign Prostatic Hyperplasia Patients Receiving Prostatic Artery Embolisation

Research
CUHK Proves Modified HIFU Treatment Effective for Treating Uterine Fibroids

CUHK Proves Modified HIFU Treatment Effective for Treating Uterine Fibroids

Research
CUHK Proves Prostate Artery Embolization Effective for Benign Prostatic Hyperplasia

CUHK Proves Prostate Artery Embolization Effective for Benign Prostatic Hyperplasia

Research
CUHK’s New Prostatic Artery Embolization Shows 90% Success Rate in Relieving Symptoms of Benign Prostatic Hyperplasia

CUHK’s New Prostatic Artery Embolization Shows 90% Success Rate in Relieving Symptoms of Benign Prostatic Hyperplasia

Clinical service
Radiotherapy to Head and Neck Raises Risk for Stroke CUHK Proved Effectiveness of Carotid Angioplasty and Stenting

Radiotherapy to Head and Neck Raises Risk for Stroke CUHK Proved Effectiveness of Carotid Angioplasty and Stenting

Research
CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

Research
Good News for Asian Patients First Local Clinical Study Shows High Success Rate and Effectiveness of Stenting for Intracranial Stenosis in Preventing Ischaemic Stroke

Good News for Asian Patients First Local Clinical Study Shows High Success Rate and Effectiveness of Stenting for Intracranial Stenosis in Preventing Ischaemic Stroke

Research
CUHK Proves the Potent Efficacy of Stenting for Carotid Artery Narrowing and Cardiac Contractility Modulation for Heart Failure

CUHK Proves the Potent Efficacy of Stenting for Carotid Artery Narrowing and Cardiac Contractility Modulation for Heart Failure

Research
CUHK World First Shows AI-derived MRI Brain Indices   Aid Clinical Detection of Three Cognitive Disorders at Early Stage

CUHK World First Shows AI-derived MRI Brain Indices Aid Clinical Detection of Three Cognitive Disorders at Early Stage

Research
CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

Research
CU Medicine Study Proves Pocket-size Mobile Echocardiographic Screening Device Effective in Detecting Thoracic Aortic Aneurysm

CU Medicine Study Proves Pocket-size Mobile Echocardiographic Screening Device Effective in Detecting Thoracic Aortic Aneurysm

Research
CUHK Discovers an Essential Oncogene in Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma

CUHK Discovers an Essential Oncogene in Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma

Research
CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

Research
CUHK Sets up the Global First Research Registry on Early Onset Dementia in Chinese Population

CUHK Sets up the Global First Research Registry on Early Onset Dementia in Chinese Population

Research
CUHK Screening Reveals 1 in 3 Older Adults in Community Suffer Brain Small Vessel Disease, Early Prevention Recommended

CUHK Screening Reveals 1 in 3 Older Adults in Community Suffer Brain Small Vessel Disease, Early Prevention Recommended

Clinical service
CUHK and PWH Introduce Leading 3D Imaging System which Reduces Radiation Dosage by 90%

CUHK and PWH Introduce Leading 3D Imaging System which Reduces Radiation Dosage by 90%

Clinical service
CUHK Establishes New Hybrid Cardiovascular Operating Theatre and Multidisciplinary Team Significantly Reducing Operation Time and Risk of Thoracic Aortic Surgery

CUHK Establishes New Hybrid Cardiovascular Operating Theatre and Multidisciplinary Team Significantly Reducing Operation Time and Risk of Thoracic Aortic Surgery

Clinical service
CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

Research
CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

Research
Antiviral Therapy Can Prevent Liver Cancer Recurrence CUHK Represents HK to Draw Up Asian Pacific Treatment Guideline for Chronic Hepatitis B

Antiviral Therapy Can Prevent Liver Cancer Recurrence CUHK Represents HK to Draw Up Asian Pacific Treatment Guideline for Chronic Hepatitis B

Research
CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

Clinical service
CUHK Pioneers MRI Iron Assessment for Thalassemia Children in Southern China

CUHK Pioneers MRI Iron Assessment for Thalassemia Children in Southern China

Clinical service
Why is Liver Cancer More Prevalent in Men than in Women? CUHK Discovers a Sex Hormone-controlled Gene that Promotes Liver Cancer

Why is Liver Cancer More Prevalent in Men than in Women? CUHK Discovers a Sex Hormone-controlled Gene that Promotes Liver Cancer

Research

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.